Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

Loading articles data…

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Readable research linked to original sources

Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

Filters

Clear all

Article type

Publication year

19172026

From yearTo year

Keyword

1 articles

Newest first

Research Article 2024CC BYCC BY allows this article to remain publicly readable here. Any reuse must still follow the recorded source terms.Free full text

Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials.

A R Müller, B den Hollander, P M van de Ven, K C B Roes, L Geertjens, H Bruining +10 more

Background Many rare genetic neurodevelopmental disorders (RGNDs) are characterized by intellectual disability (ID), severe cognitive and behavioral impairments, potentially diagnosed as a comorbid autism spectrum disorder or attention-deficit hyperactivity disorder. Quality of life is often impaired due to irritability, aggression and self-injurious behavior, generally refractory to standard therapies. There are…

BMC Psychiatry Europe PMC↗

Open article record in new tab ↗

End of results

The service organizes published evidence. It does not provide medical advice.